Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07024953

The Agenda-Setting for Kidney Disease Trial

The goal of this clinical trial is to learn if a tool with a list of discussion topics, called a structured clinical visit agenda-setting intervention (SAS), works for people with advanced chronic kidney disease (CKD) who receive care at a clinic that serves people who live in rural areas. The SAS is called CKD Topics. The researchers will compare the SAS intervention to usual care (the way clinicians usually practice) to see how well it works for people with advanced CKD. This is a special type of clinical trial called a stepped wedge randomized clinical trial (RCT). In this type of trial, every participant will get to experience both usual care and CKD Topics, but for different amounts of time.

The researchers will learn if doing a clinical trial of CKD Topics is possible (feasible) and get information about how well CKD Topics helps people with advanced CKD shape visit discussions (self-advocacy) in their appointments with their clinicians. The information the researchers collect in this trial will help design a future trial with more participants.

The main questions the researchers aim to answer are:

* Is it possible to conduct this type of study of a SAS intervention? i.e. feasibility * Does the SAS intervention help people with advanced CKD shape discussions (self-advocacy) with their clinicians? If so, how much? i.e. preliminary efficacy

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

This stepped-wedge pilot randomized controlled trial (RCT) is to test a new structured agenda-setting (SAS), called the Chronic Kidney Disease (CKD) Topics Agenda-Setting Tool, with patients, their care partners and their clinicians. This is a pilot study, so the researchers are collecting feasibility data to determine if a larger, fully-powered RCT can be moved forward. The researchers are also collecting preliminary efficacy data, which will help the design of a future study on the efficacy of clinical visits for people with advanced CKD.

This study has two arms: 1) a usual care arm, and 2) an intervention arm where participants and their nephrology physicians will use CKD Topics during their visits. Physicians will initially be randomly assigned to one of three clusters, with two attending physicians and one fellow physician in each cluster. Each cluster will start out practicing usual care for at least eight months during the enrollment period. After that initial 8 months, one cluster will cross over to the intervention arm every four months, by using the CKD Topics tool in their visits, in what's called the rollout period. At 16 months into the trial, all clusters will be on the intervention arm, using CKD topics with patients, and will do so for the remaining 12 months of the trial.

Patient participants will be enrolled in the study arm to which their physicians have been randomized. Participation is expected to last 24 months for patients and clinicians, and participants may use CKD Topics more than once during the study period. The researchers expect 108 patient participants, and nine clinicians will enroll in the study. Every participant will receive a baseline survey after enrollment and four subsequent surveys.

The procedures in this study will include screening patients for study eligibility, consenting them to participate in study activities such as filling out surveys. The intervention, CKD topics, itself will be administered as quality improvement so will not be included as a research activity needing consent.

Future Directions: Findings from this trial will forecast a range of participants required in the sample for a full-scale RCT and illustrate "proof of concept" for a future trial which will evaluate the intervention's impact on patient self-advocacy and clinical care outcomes in rural CKD populations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults >18 years old who have been diagnosed with advanced CKD (stages 4-5).
  • Care partners, clinicians and staff supporting these CKD patients who are willing and able to provide informed consent
  • English-speaking
  • Able to provide informed consent
  • Patient must be attending outpatient visits *(in-person and/or telehealth allowable).

Exclusion criteria

  • Children under 18 years old will not be included
  • Non-English-speaking patients and/or care partners
  • Patients on dialysis
  • Individuals unable or unwilling to provide informed consent

Treatment and study plan

Chronic Kidney Disease Structured Agenda-Setting Tool

Other

Chronic Kidney Disease (CKD) Topics is a novel clinical visit agenda-setting intervention developed through participatory research methods for people with CKD living in rural areas. CKD Topics includes structured discussion topic areas.

Primary outcomes

  1. Primary Feasibility Outcome

    Time frame: From enrollment to the end of treatment at 16 months

    The primary outcome will be feasibility, assessed by the proportion of patients who received the intervention.

Secondary outcomes

  1. Secondary Feasibility Outcome

    Time frame: From enrollment to the end of treatment at 16 months

    The secondary outcome will be feasibility assessed by the clinicians' intention to continue the intervention use, measured in a survey.

Other outcomes

  1. Primary Process Outcome: Enrollment Rate

    Time frame: From enrollment to the end of treatment at 16 months

    As measured by participant enrollment in Redcap.

  2. Secondary Process Outcome: Loss to follow-up

    Time frame: From enrollment to the end of treatment at 16 months

    As measured by participant dropout (loss to follow-up) in Redcap.

  3. Preliminary Efficacy Outcome: Patient Self-Advocacy Scale (PSAS)

    Time frame: From enrollment to the end of treatment at 16 months

    The Patient Self-Advocacy Scale (PSAS); a 12-item validated scale assessing the latent construct of perceived self-advocacy for patients.

  4. Preliminary Efficacy Outcome: Patient self-efficacy

    Time frame: From enrollment to the end of treatment at 16 months

    Patient self-efficacy measured using the Ask, Understand, Remember Assessment, (AURA); a validated 4-item assessment of self-efficacy completed by patients.

  5. Preliminary Efficacy Outcome: Patient self-management

    Time frame: From enrollment to the end of treatment at 16 months

    Patient demonstration of self-management using the Perceived Medical Condition Self-Management Scale; an 8-item instrument validated to assess self-management among CKD patients; correlated with treatment adherence.

  6. Preliminary Efficacy Outcome: Unplanned hospitalization or emergency department visit

    Time frame: From enrollment to the end of treatment at 16 months

    Unplanned hospitalization or emergency department visit. EHR chart review and patient self-report.

  7. Preliminary Efficacy Outcome: Serious Illness Experience

    Time frame: From enrollment to the end of treatment at 16 months

    Serious illness experience measured by the consideRATE questions; a validated 8-item, plain language (2nd grade) patient-reported experience measure (PREM) with Likert-like response options for patients, and care partners.

  8. Preliminary Efficacy Outcome: Respect Experience Assessment

    Time frame: From enrollment to the end of treatment at 16 months

    Respect experience assessment measured by the "Heard and Understood" tool. Heard and Understood is a validated Single-item PREM with Likert-like response options for patients.

Study contacts

Contact information is provided by the study sponsor or research team.

Anne E. Dade, Research Associate, MPP

CONTACT

[email protected]

Catherine H. Saunders, Assistant Professor of Medicine and of Health Policy, PhD, MPH

CONTACT

[email protected]

603-653-3436

Sponsors and collaborators

Lead sponsor

Dartmouth-Hitchcock Medical Center

Other

Collaborators

  • Dartmouth College
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • University of Washington

Registry information

Official study title

Setting the Agenda: A Pilot Stepped Wedge Cluster Randomized Trial of a Structured Clinical Visit Agenda-Setting Intervention for Rural-Residing People With Advanced Chronic Kidney Disease

Acronym: ASK

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Jun 17, 2025
Registry last updated
Jun 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.